icon-folder.gif   Conference Reports for NATAP  
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
Time to Viral Suppression [week 2/4] Is Not Related to Achievement of SVR12 in HCV GT1-infected Patients Treated With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin
  Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Mark Sulkowski1, Michael W Fried2, Resat Ozaras3, Vasily Isakov4, David Wyles5, Peter Ferenci6, Jordan J Feld7, Filipe Calinas8, Michael Gschwantler9, Darrell Crawford10, Ira M Jacobson11,
Barbara McGovern12, Marti n King12, Edward Gane13
1Johns Hopkins University, Baltimore, Maryland, United States; 2University of North Carolina at Chapel Hill, North Carolina, United States; 3Cerrahpasa Medical School, Istanbul, Turkey; 4Institute of Nutrition, Moscow, Russia; 5University of California San Diego, La Jolla, California, United States; 6Universitaetsklinik fuer Innere Medizin III, Vienna, Austria; 7University of Toronto, Toronto, Ontario, Canada; 8Hosp. St. Antonio dos Capuchos, Lisbon, Portugal; 9Wilhelminenspital, Vienna, Austria; 10University of Queensland, Brisbane, Australia;
11Weill Cornell Medical College, New York, New York, United States; 12AbbVie Inc., North Chicago, Illinois, United States; 13Auckland City Hospital, Auckland, New Zealand
......."achievement of SVR12 was not associated with time to viral suppression [week 2 or 4] as assessed by assays examining HCV RNA <25 IU/mL or <15 IU/mL.......Higher baseline HCV RNA level, older age, GT1b subtype, and presence of cirrhosis were associated with a longer time to initial viral suppression <25 IU/mL, but the magnitude of the effect was small and ti me to suppression did not affect achievement of SVR12"